← All stories
Markets
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug development and global comme…
Covered by 1 outlet
All coverage · 1 article